SAN ANTONIO, Dec. 5, 2017 /PRNewswire/ -- Research presented
today by Invitae Corporation (NYSE: NVTA), one of the fastest
growing genetic information companies, shows how clinicians are
using genetic testing beyond BRCA1 and BRCA2 to guide
treatment and screening decisions for hereditary breast and ovarian
cancer (HBOC) patients and their families. The data are being
presented at the 2017 San Antonio Breast Cancer Symposium.
Earlier research from Invitae published in the October issue of
Annals of Surgical Oncology shows that when multigene panels
are used with breast cancer patients, most non-BRCA variants
identified are in clinically actionable genes with defined
management guidelines. Two studies presented in San Antonio looked at the prevalence of
non-BRCA findings and their utility for patient care.
First, an analysis of patients who received germline testing
following somatic testing of breast tumor samples found that
germline BRCA1/2 findings were identified in nearly half of
patients and a substantial portion also had at least one germline
variant outside BRCA1/2. An additional study evaluated how
patients with non-BRCA findings are managed by clinicians
and found that their test results altered clinical management,
including implementing increased surveillance, additional family
testing, and other treatment modifications.
"Our understanding of the genes associated with HBOC risk has
continued to grow and a number of genes outside BRCA1 and
2 are known to confer added risk of disease. This research
shows that for both germline and somatic testing, important
information about hereditary cancer syndrome genes besides
BRCA1/2 may be identified in HBOC patients," said
Robert Nussbaum, MD, chief medical
officer of Invitae. "These studies confirm that those findings are
most often clinically actionable. Together, the results suggest
that expanding guidelines to also address the identification and
management of non-BRCA variants could improve care for HBOC
patients and their families."
Full research presentation schedule
The full schedule of the Invitae presentations at the meeting is
as follows:
Wednesday, December 6:
- PD1-03: Clinically actionable pathogenic mutation that may be
missed by conventional NGS-based testing: An analysis of 80,000
patients | Presented by Steve
Lincoln, Invitae | 5:00 pm
CT
Thursday, December 7:
- P3-03-01: Clinical utility of finding pathogenic mutations
beyond BRCA1/2 in breast cancer patients | Presented by
Ed Esplin, MD, PhD, FACMG, Invitae |
5:00 pm CT
Friday, December 8:
- P4-06-02: Germline analysis of breast cancer patients with
abnormal somatic results: Ancillary assessment or critical
co-diagnostic? | Presented by Ed
Esplin, MD, PhD, FACMG, Invitae | 7:00 am CT
- P4-06-08: An interlaboratory study of complex mutation
detection in genes associated with hereditary breast and ovarian
cancer highlights both successes and current challenges | Presented
by Steve Lincoln, Invitae |
7:00 am CT
- P4-06-09: Addition of a remote genetic counselor to the breast
specialist's team improves clinical decision-making | Presented by
Barry Rosen, MD, Advocate Health |
7:00 am CT
About Invitae
Invitae Corporation's (NYSE: NVTA)
mission is to bring comprehensive genetic information into
mainstream medical practice to improve the quality of healthcare
for billions of people. Specializing in genetic diagnostics in
clinical areas across all stages of life, Invitae is aggregating
the world's genetic tests into a single service with better
quality, faster turnaround time, and lower prices. The company
provides a variety of diagnostic tests with clinical utility in
preimplantation and carrier screening for inherited disorders,
miscarriage analysis, pediatric and developmental disorders,
neurological disorders, cardiovascular disorders, metabolic
disorders, and hereditary cancers. For more information, visit our
website at
invitae.com.
Safe Harbor Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements that
multi-gene genetic testing could improve identification and
management of hereditary cancer risk for breast cancer patients and
their families; that important information about hereditary cancer
syndrome genes besides BRCA may be identified in hereditary breast
and ovarian cancer (HBOC) patients; and that expanding the
guidelines to address identification and management of non-BRCA
genetic variants could improve care for HBOC patients and their
families. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: risks associated with the company's ability to use
rapidly changing genetic data to interpret test results accurately,
consistently, and quickly; the company's history of losses; the
company's need to scale its infrastructure in advance of demand for
its tests and to increase demand for its tests; the company's
ability to develop and commercialize new tests and expand into new
markets; the risk that the company may not obtain or maintain
sufficient levels of reimbursement for its tests; laws and
regulations applicable to the company's business; and the other
risks set forth in the company's filings with the Securities and
Exchange Commission, including the risks set forth in the company's
Quarterly Report on Form 10-Q for the quarter ended September 30, 2017. These forward-looking
statements speak only as of the date hereof, and Invitae
Corporation disclaims any obligation to update these
forward-looking statements.
Contact:
Laura D'Angelo
pr@invitae.com
314-920-0617
View original content with
multimedia:http://www.prnewswire.com/news-releases/multigene-genetic-testing-improves-identification-and-management-of-hereditary-cancer-risk-for-breast-cancer-patients-and-their-families-300566437.html
SOURCE Invitae Corporation